Physician profile
Devon A Carr
NPI 1558704999
$3,716.54
in general payments reported to CMS, 2019-2025
37 companies · $683 in 2025
The $683 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $259 · 2021: $705 · 2022: $474 · 2023: $583 · 2024: $816 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.54 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $384.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $374.62 | 2019-2025 | Trelegy Ellipta, Pediarix, Bexsero |
| Lilly USA, LLC | $310.68 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $257.73 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $198.17 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $122.18 | 2020-2021 | |
| Esperion Therapeutics, INC. | $105.54 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $99.09 | 2019-2023 | |
| Mylan Specialty L.P. | $98.96 | 2024 | Yupelri |
| Pfizer INC. | $95.86 | 2019-2025 | |
| Exact Sciences Corporation | $89.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $85.81 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $83.48 | 2021-2022 | |
| Axsome Therapeutics, INC. | $68.78 | 2024-2025 | Auvelity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.